Amphastar Grows with Biosimilars and Generics | Business and Finance News

Amphastar Pharmaceuticals is on a strong financial roll, reporting $184 million in Q2 revenue — up from both last quarter and last year — while advancing across three key pillars: expanding commercial products, developing complex generics and biosimilars, and pushing proprietary drug pipelines. BAQSIMI continues to dominate with 17% year-over-year prescription growth, despite slight sales dips from pricing; Primatene MIST sees solid demand, and a new ipratropium bromide launch showcases their manufacturing prowess. An FDA warning letter for IMS is being addressed without expected operational impact, while U.S. manufacturing upgrades aim to boost efficiency. Looking ahead, they’re preparing for potential insulin aspart biosimilar launch in 2027, running Phase 1 trials for an epinephrine nasal spray, and advancing oncology and ophthalmology programs — all reinforcing their diversified, value-driven strategy. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b111c1c3fd9af094